These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24164086)

  • 41. New Analogues of the Nicotinamide Phosphoribosyltransferase Inhibitor FK866 as Potential Anti-Pancreatic Cancer Agents.
    Conforti I; Benzi A; Caffa I; Bruzzone S; Nencioni A; Marra A
    Med Chem; 2024; 20(7):694-708. PubMed ID: 38333979
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
    Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
    Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
    Zhang K; Ni Y; Chen J; Tu Z; Wu X; Chen D; Yao H; Jiang S
    Bioorg Med Chem Lett; 2019 Jun; 29(12):1502-1506. PubMed ID: 30992165
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.
    Huang XF; Lu X; Zhang Y; Song GQ; He QL; Li QS; Yang XH; Wei Y; Zhu HL
    Bioorg Med Chem; 2012 Aug; 20(16):4895-900. PubMed ID: 22819191
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
    Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
    Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
    J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors.
    Zhang YB; Wang XL; Liu W; Yang YS; Tang JF; Zhu HL
    Bioorg Med Chem; 2012 Nov; 20(21):6356-65. PubMed ID: 23018096
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis and biological evaluation of novel oxadiazole derivatives: a new class of thymidine phosphorylase inhibitors as potential anti-tumor agents.
    Shahzad SA; Yar M; Bajda M; Jadoon B; Khan ZA; Naqvi SA; Shaikh AJ; Hayat K; Mahmmod A; Mahmood N; Filipek S
    Bioorg Med Chem; 2014 Feb; 22(3):1008-15. PubMed ID: 24411198
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
    Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
    Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors.
    Sadrerafi K; Mason EO; Lee MW
    Drug Des Devel Ther; 2018; 12():987-995. PubMed ID: 29731606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structure-based drug design of novel carborane-containing nicotinamide phosphoribosyltransferase inhibitors.
    Asawa Y; Katsuragi K; Sato A; Yoshimori A; Tanuma SI; Nakamura H
    Bioorg Med Chem; 2019 Jul; 27(13):2832-2844. PubMed ID: 31103405
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
    Travelli C; Aprile S; Mattoteia D; Colombo G; Clemente N; Scanziani E; Terrazzino S; Alisi MA; Polenzani L; Grosa G; Genazzani AA; Tron GC; Galli U
    Eur J Med Chem; 2019 Nov; 181():111576. PubMed ID: 31400709
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation.
    Wen F; Gui G; Wang X; Qin A; Ma T; Chen H; Li C; Zha X
    J Med Chem; 2024 Jun; 67(11):8667-8692. PubMed ID: 38651495
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of novel NAMPT inhibitors based on pharmacophore modeling and virtual screening techniques.
    Yi Q; Zhou L; Shao X; Wang T; Bao G; Shi H; Zhou S; Li X; Tian Y
    Comb Chem High Throughput Screen; 2014; 17(10):868-78. PubMed ID: 25413783
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
    Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
    Travelli C; Aprile S; Rahimian R; Grolla AA; Rogati F; Bertolotti M; Malagnino F; di Paola R; Impellizzeri D; Fusco R; Mercalli V; Massarotti A; Stortini G; Terrazzino S; Del Grosso E; Fakhfouri G; Troiani MP; Alisi MA; Grosa G; Sorba G; Canonico PL; Orsomando G; Cuzzocrea S; Genazzani AA; Galli U; Tron GC
    J Med Chem; 2017 Mar; 60(5):1768-1792. PubMed ID: 28165742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy.
    Ozgencil F; Gunindi HB; Eren G
    Bioorg Chem; 2024 Aug; 149():107509. PubMed ID: 38824699
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
    Sampath D; Zabka TS; Misner DL; O'Brien T; Dragovich PS
    Pharmacol Ther; 2015 Jul; 151():16-31. PubMed ID: 25709099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.